Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

STRASS2 : A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients With High Risk RetroPeritoneal Sarcoma (RPS)

Male or<br/>FemaleGender Male or

RecruitingStatus Recruiting


ThreePhase Three

18+Age Over 18

Sarcoma<br/>CancersCancer LocationSarcoma

Surgical,Systemic therapy,Treatment | SarcomaLeiomyosarcoma,Liposarcoma

Trial Overview Read MoreRead more

This phase III study is trying to determine whether having chemotherapy before surgery is more effective than surgery alone in people with dedifferentiated liposarcoma and leiomyosarcoma.

This trial is treating patients with liposarcoma and leiomyosarcoma.

This is a systemic therapy and surgical trial.

You may be able to join this trial if:

  • You have been diagnosed with cancer, but have not received any treatment.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients With High Risk RetroPeritoneal Sarcoma (RPS)

Cooperative Group

European Organisation for Research and Trearment of Cancer (EORTC)


Eligible participants will be randomly allocated to either the Standard Arm or the Experimental Arm. In the Standard Arm, participants will receive large en-bloc curative-intent surgery within 4 weeks following randomisation. In the Experimental Arm, participants will receive 3 cycles of neoadjuvant chemotherapy starting within 2 weeks following randomisation. People with liposarcoma will receive ADM (doxorubicin) 75mg/m2 (or the equivalent EpiADM 120mg/m2) + ifosfamide 9g/m3 every 3 weeks. People with leiomyosarcoma will receive ADM 75mg/m2 + DTIC (dacarbazine) 1g/m2 every 3 weeks. Following this, participants in the experimental arm will be re-assessed to determine whether surgery can proceed. If yes, curative-intent surgery will be performed within 3-6 weeks of last cycle of chemotherapy.

Recruiting Hospitals Read MoreRead more

PCCTU (Parkville Cancer Clinical Trials Unit) *
Nicole Marsh

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.